drugset / Trial / NCT03193918
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm phase I/Ib study of crenolanib combined with ramucirumab/paclitaxel as second line therapy for patients with advanced/metastatic adenocarcinoma of the esophagus, GEJ or stomach. Patients will be enrolled in two phases; dose escalation phase and dose expansion phase.
Timeline
- Start
- 2017-04-14
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crenolanib | Small molecule | 60 mg | — |
| Subject | Crenolanib | Small molecule | 80 mg | — |
| Subject | Crenolanib | Small molecule | 100 mg | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |
| Background | Ramucirumab | Monoclonal antibody | 8 mg/kg | Intravenous |